注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、免疫抑制治疗、血液疾病和肿 瘤的治疗、休克的治疗等。2024年津药和平向巴拿马共和国卫生部提出注册申请，2025年11月收到卫生 部通知，取得注册证书。根据IQVIA数据库显示，甲泼尼龙类注射剂2023年、2024年全球市场销售额分 别为5.26亿美元、5.21亿美元。 津药和平注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书，将为制剂业务拓展巴拿马市场带 来新机遇，也将进一步推动公司国际化战略布局。 格隆汇11月18日丨津药药业(600488.SH)公布，公司子公司津药和平（天津）制药有限公司注射用甲泼 尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书（标志着可以生产并在巴拿马共和国市场销售该产 品）。药品名称：注射用甲泼尼龙琥珀酸钠，批准文号：210124。 ...

Core Viewpoint - The company, Olin Bio, is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [2] Group 1: Company Strategy - The company aims to deepen its international strategic layout and increase its global recognition and influence [2] - The initiative is part of a broader effort to strengthen the company's overall competitive capabilities [2] Group 2: Listing Process - Currently, the company is in discussions with relevant intermediaries regarding the H-share listing [2] - Specific details about the H-share listing are yet to be determined [2] - The listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]

Group 1 - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and influence [1] - This initiative is part of the company's strategy to deepen its internationalization and optimize its capital structure [1] - The goal is to strengthen the company's overall competitiveness in the market [1]